Jaguar Health, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025

Published on 15/05/2025 at 23:31

S&P Capital IQ

+1.67%

Jaguar Health, Inc. reported earnings results for the first quarter ended March 31, 2025. For the first quarter, the company reported revenue was USD 2.21 million compared to USD 2.35 million a year ago. Net loss was USD 10.46 million compared to USD 9.23 million a year ago.

Basic loss per share from continuing operations was USD 16.7 compared to USD 87.12 a year ago.

Latest news about Jaguar Health, Inc.

Jaguar Health to Seek European Regulatory Approval for Dog Diarrhea Treatment	25/06	MT
Jaguar Health Establishes First Site for Canalevia-CA1 Field Study	11/06	MT
Jaguar Health Prices Offering of Shares, Warrants	21/05	MT
Jaguar Health, Inc., Q1 2025 Earnings Call, May 15, 2025	19/05
Jaguar Health, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	15/05	CI
Jaguar Health, Inc. - Special Call	30/04
Jaguar Health, Inc. and Napo Therapeutics Announce Initial Proof-Of-Concept Results	30/04	CI
Jaguar Health, Inc., Q4 2024 Earnings Call, Mar 31, 2025	31/03
Jaguar Health, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	31/03	CI
Jaguar Health, Inc. announced that it has received $3.4 million in funding	31/03	CI
Jaguar Health, Inc. Auditor Raises 'Going Concern' Doubt	31/03	CI
Sector Update: Health Care Stocks Lower Late Afternoon	27/03	MT
Sector Update: Health Care Stocks Retreat Wednesday Afternoon	26/03	MT
Sector Update: Health Care	26/03	MT
Jaguar Health Executives Invest in $3.5 Million Bridge Financing; Shares Fall	26/03	MT
Jaguar Health, Inc. announced that it expects to receive $3.4 million in funding	26/03	CI
Jaguar Health to Implement 1-for-25 Reverse Stock Split	18/03	MT
Jaguar Health, Inc. and Napo Pharmaceuticals, Inc. Enter into an Amendment with Streeterville Capital, LLC	21/02	CI
Jaguar Health, Inc., Q3 2024 Earnings Call, Nov 13, 2024	13/11
Earnings Flash (JAGX) JAGUAR HEALTH Posts Q3 Revenue $3.1M	13/11	MT
Jaguar Health, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	13/11	CI
FDA Approves Renewal of Canalevia-CA1, Jaguar Health, Inc.'s Drug for Chemotherapy-Induced Diarrhea in Dogs	06/11	CI
Jaguar Health to Spotlight Company's Commercial Focus on Cancer Supportive Care At American Society for Radiation Oncology Annual Meeting for FDA-Approved Gelclair Oral Mucositis Product in Advance of October 2024	24/24/24	CI
Jaguar Health Awarded Patent in Jordan for Short Bowel Syndrome Treatment	27/24/27	MT
Jaguar Health Reports Issue of Hong Kong Patent for Short Bowel Syndrome Treatment Methods	19/24/19	MT